Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Addressing the limitations of the current leading COVID-19 vaccines could be the key to long-term success.

This Late-to-the-Party Coronavirus Vaccine Maker Could Be the Biggest Winner Over the Long Run

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Present New Data from the Company’s Diverse HIV Portfolio and Pipeline at HIV Glasgow 2020

Merck to Present New Data from the Company’s Diverse HIV Portfolio and Pipeline at HIV Glasgow 2020

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Hold Third-Quarter 2020 Sales and Earnings Conference Call on October 27

Merck to Hold Third-Quarter 2020 Sales and Earnings Conference Call on October 27

Celyad Oncology (CYAD) collaborates with Merck to evaluate its CAR-T candidate, CYAD-101,combined with the latter's Keytruda in microsatellite stable refractory metastatic colorectal cancer.

Celyad-Merck Team Up to Evaluate CYAD-101 in Colorectal Cancer

Lam Research

Microsoft

Target

Texas Instruments

Given strong dividend growth and big money signals, these stocks could be worth a spot in a yield-oriented portfolio.

Best Dividend Stocks for October 2020

MADISON, N.J.--(BUSINESS WIRE)---- $MRK #ForThemForUs--Merck Animal Health Supports Rabies Elimination by 2030 on World Rabies Day

Merck Animal Health Supports Rabies Elimination by 2030 on World Rabies Day

Bayer AG

Biogen

Bank of New York Mellon

Bristol-Myers

British American Tobacco

Cerner

GlaxoSmithKline

Imperial Brands PLC

Intel

Altria

Philip Morris

Roche Holding AG

Wide-Moat Stocks On Sale - The October 2020 Heat Map

In the latest trading session, Merck (MRK) closed at $82.63, marking a -0.37% move from the previous day.

Merck (MRK) Stock Moves -0.37%: What You Should Know

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus Chemotherapy Reduced Risk of Death by 27% Vs Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Esophageal Cancer

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Esophageal Cancer

AstraZeneca

The European Medicines Agency (EMA) has recommended approval for Lynparza in patients with a form of prostate cancer and as a first-line maintenance treatment for a form of advanced ovarian cancer, the British drugmaker AstraZeneca said on Monday.

EU agency recommends AstraZeneca-Merck drug Lynparza for two cancers

Apple

Axovant Gene Therapies Ltd

American Express

JPMorgan Chase & Co

Coca-Cola

McDonald's

NIKE

Pfizer

Sutro Biopharma Inc

Walmart

Sio Gene Therapies

Week 39 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced final results from the Phase III PROfound trial that showed LYNPARZA (olaparib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus enzalutamide or abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 or ATM gene mutations, a subpopulation of homologous recombina

LYNPARZA® (olaparib) Reduced the Risk of Death by 31% in BRCA1/2 or ATM-mutated Metastatic Castration-Resistant Prostate Cancer in Phase III Profound Trial

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--LYNPARZA Reduced Risk of Death by 31% for Men with BRCA1/2 or ATM-Mutated mCRPC Who Progressed Following Enzalutamide or Abiraterone in Ph 3 Trial

LYNPARZA Reduced Risk of Death by 31% vs. Enzalutamide or Abiraterone for Men with BRCA1/2 or ATM-Mutated Metastatic Castration Resistant Prostate Cancer Who Progressed Following Enzalutamide or Abiraterone in Phase 3 PROfound Trial

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Presents Promising New Data for Three Investigational Medicines From Diverse and Expansive Oncology Pipeline at ESMO Virtual Congress 2020

Merck Presents Promising New Data for Three Investigational Medicines From Diverse and Expansive Oncology Pipeline at ESMO Virtual Congress 2020

KENILWORTH, N.J., & WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types

Merck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020

KENILWORTH, N.J., & BRUSSELS--(BUSINESS WIRE)---- $MRK #MRK--Merck’s KEYTRUDA Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma

Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma

Merck & Co., Inc. (MRK) Management Presents at Cantor Fitzgerald Virtual Global Healthcare Conference (Transcript)

ORANGE COUNTY, Calif., Sept. 16, 2020 /PRNewswire/ -- Baum Hedlund Aristei & Goldman filed a Gardasil vaccine injury lawsuit today against manufacturer Merck on behalf of a young man who sustained life-altering injuries he alleges were caused by the HPV vaccine.

Baum Hedlund Files Gardasil Lawsuit Against Merck on Behalf of Man

Gilead Sciences

Immunomedics

NVIDIA

Oracle

Seagen

It’s an exciting time for mergers and acquisitions in some of the hottest sectors -- including software, cloud services, artificial intelligence and health care. Here are four major mergers to watch.

Merger Mania: 4 Major Deals to Watch

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Hold Investor Briefing Following ESMO Virtual Congress 2020

Merck to Hold Investor Briefing Following ESMO Virtual Congress 2020

PetMed Express

VanEck Vectors Pharmaceutical ETF

These trio of pets stocks to buy offers global potential for investors looking to play the growing trend of owning a furry friend.
The post 3 Pet Stocks to Buy for Your Furry Friend appeared first on InvestorPlace.

3 Pet Stocks to Buy for Your Furry Friend

Some traders consider Merck stock to be a safe Dow Jones type of investment. Yet, the Covid-19 vaccine angle could propel the share price.

Merck Could Be the Covid-19 Investment You’re Missing

Seattle Genetics (SGEN) strikes a couple of deals with Merck to co-develop ladiratuzumab vedotin for breast cancer and other solid tumors. Also, Merck will market the company's Tukysa in some places.

Seattle Genetics Up on Two New Oncology Deals With Merck

Morgan Stanley

Merck & Co., Inc. (MRK) CEO Ken Frazier Presents at Morgan Stanley 18th Annual Global Healthcare Conference (Transcript)

Merck (MRK) buys rights to co-develop/co-commercialize Seattle Genetics' ladiratuzumab vedotin. It acquires exclusive license to commercialize Tukysa for HER2-positive cancers in Asia, the Middle East and Latin America

News for Merck Stock (MRK)